New immune cell therapy targets Hard-to-Treat cancers
NCT ID NCT07474168
First seen Mar 20, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recognize and attack cancer cells while also resisting tumor-suppressing signals. The study aims to check safety and see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Zhejiang University school of Medicine
Hangzhou, Zhejiang, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TCR-T cells targeting KRAS G12V mutation
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have a specific KRAS mutation and no other standard treatments.
What could go wrong
This is a very early, small Phase 1 trial with only 9 participants, so results may not apply to everyone. The therapy is experimental and may cause side effects or not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.